- $525.25m
- $513.94m
- $0.04m
Entera Bio Ltd reports results for the quarter ended in March - Earnings Summary
Entera Bio Ltd expected to post a loss of 7 cents a share - Earnings Preview
Brief: Entera Bio Announces Q1 2023 Financial Results
Brief: Menopause Luminary, Steven Goldstein, Joins Entera's Clinical And Scientific Advisory Board
Brief: Entera Bio Regains Compliance With Nasdaq Listing Requirements
Entera Bio Ltd expected to post a loss of 11 cents a share - Earnings Preview
Entera Bio Ltd expected to post a loss of 11 cents a share - Earnings Preview
Entera Bio Ltd expected to post a loss of 11 cents a share - Earnings Preview
Brief: Entera Bio Ltd Receives Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Entera Bio Ltd reports results for the quarter ended in September - Earnings Summary
Brief: Entera Bio Provides Financial Results For The Third Quarter Of 2022
Entera Bio Ltd expected to post a loss of 13 cents a share - Earnings Preview
Brief: Entera Bio Announces FDA Agreement For A Single Phase 3 Clinical Trial To Support An NDA For EB613
Brief: Entera Bio Presents Dose Proportional Absorption And Correlation To BMD Clinical Response Data From Its Phase 2 Study Of EB613 In Post-Menopausal Osteoporosis Patients At The ASBMR 2022 Annual Meeting
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
H.C. Wainwright starts coverage of Entera Bio with 'buy' rating
Brief: Entera Bio-Entered Into Sales Agreement With SVB Securities LLC, Relating To Issuance, Sale, From Time To Time, Of Up To 5 Million Of Co’s Ordinary Shares
Entera Bio Ltd reports results for the quarter ended in June - Earnings Summary
Brief: Entera Bio reports Q2 results